Triglav Skladi’s Neurocrine Biosciences NBIX Stock Holding History

Triglav Skladi’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.19M	Sell	9,000 -1,000	-10%	-$133K	0.08%	113
2025 Q4	$1.42M	Sell	10,000 -1,000	-9%	-$145K	0.09%	114
2025 Q3	$1.54M	Hold	11,000	–	–	0.1%	92
2025 Q2	$1.38M	Hold	11,000	–	–	0.1%	98
2025 Q1	$1.22M	Hold	11,000	–	–	0.1%	94
2024 Q4	$1.5M	Buy	+11,000	New	+$1.36M	0.12%	87

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Triglav Skladi's NBIX Position: Q1 2026 in Review

Triglav Skladi reduced its Neurocrine Biosciences (NBIX) stake by 10% in Q1 2026, selling an estimated $133K and leaving 9,000 shares worth $1.19M. The position accounts for 0.08% of the portfolio, ranked #113.

Triglav Skladi first reported a position in NBIX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.54M in Q3 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Triglav Skladi held 9,000 shares of Neurocrine Biosciences worth $1.19M as of Q1 2026.
Triglav Skladi sold 1,000 Neurocrine Biosciences shares in Q1 2026, an estimated $133K.
Neurocrine Biosciences made up 0.08% of Triglav Skladi's portfolio in Q1 2026, its #113 holding.
Triglav Skladi first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 6 quarters since.
Triglav Skladi's Neurocrine Biosciences position peaked at $1.54M in Q3 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Triglav Skladi's 13F filing for Q1 2026, filed 4 May 2026.